Osivax and GC Biopharma announced a strategic collaboration focused on developing a next-generation influenza vaccine. The vaccine will combine OVX836 and GC FLU. Osivax gained those rights to advance a combined shot.
Older adults are facing four vaccine decisions this fall, while the federal schedule still lists a 2025 date. Flu and pneumonia deaths have declined for 25 years, but one American age group posted an uptick.